Welcome to The Catalyst
Change isn't quick. Unless it's when you experience Intravascular Lithotripsy (IVL) for the first time. Stay apprised of our latest news and insights while discovering how a simple and intuitive tool can be The Catalyst to change the way you think about calcium modification.
In a few weeks, we are headed to a city known for its sunshine and southern hospitality, Atlanta, Georgia, where SCAI 2022 is taking place this year. At the conference, leading calcium experts will share the 1-year results from the Randomized Disrupt PAD III Trial and 1-year sex specific outcomes with Coronary IVL.
Topics: Coronary IVL, IVL Case, Peripheral IVL, Shockwave Breaking News, IVL Technology, DISRUPT PAD, Coronary Cases, Peripheral Cases, PAD Applications - BTK, Peripheral Conferences, SWAV News, Shockwave C2, Coronary Conferences, Shockwave M5, Shockwave S4, PAD Applications - TEVAR, Coronary IVL - U.S., ShockwaveM5+
2021 was Shockwave’s best year yet! Although it brought challenges, with it came immense opportunities which allowed us to grow and exceed expectations. As we push on into 2022, we are excited for what the year will bring but most importantly, for the opportunities to continue to help improve patient outcomes across the globe. But before we get started, let’s review the highlights of last quarter. We released four data releases, including our 1-year results of our Coronary IVL pivotal study at TCT this year, making it a monumental event. We had some exciting peer-reviewed publications come out, enrolled the first patient in the Disrupt BTK II Study, and much more. Read the latest PulsePoint for all the updates!
Topics: Coronary IVL, IVL Case, Peripheral IVL, IVL Technology, Coronary Cases, Peripheral Cases, Shockwave C2, Shockwave M5, Shockwave S4, PulsePoint Newsletter, Coronary IVL - U.S.
Winter is coming… and fast but before we enter the final home stretch of the year, let’s recount the milestones of the recent quarter in the latest edition of the PulsePoint Newsletter. Shockwave hit the ground running this quarter by bringing on various IVL experts from across the globe to discuss all things calcium on the ChalkTalk Podcast Series. Shockwave also made headlines in CathLab Digest with several physician-authored perspectives about the role of the technology in clinical practice. And it was great to finally get back to live, in-person conferences like VIVA ’21, where the results from the first 752 patients in the Disrupt PAD III Observational Study were presented. Catch up on what you may have missed and don’t forget watch the CalciumMasterclass.com series finale!
Topics: Coronary IVL, IVL Case, Peripheral IVL, IVL Technology, Coronary Cases, Peripheral Cases, Shockwave C2, Shockwave M5, Shockwave S4, PulsePoint Newsletter, Coronary IVL - U.S.
Shockwave has been making waves this summer! As you dive into this edition of the PulsePoint Newsletter, you’ll see that JACC: Cardiovascular Interventions published a trilogy of peer-reviewed publications highlighting Shockwave’s MOA, a pooled analysis of the 4 Disrupt CAD studies, and Disrupt PAD lll. Dive deeper and you’ll discover the incredible 10-webinar series called Calcium Masterclass that was launched at the beginning of the quarter. Explore how Shockwave was granted transitional pass-through reimbursement for Coronary IVL and proposed additional payment for hospital in-patient Coronary IVL cases performed in the United States. This PulsePoint has a lot to cover – recap the rest of the events and milestones from an exciting last quarter. But as you relax on your vacation, always stay on the pulse!
Topics: Coronary IVL, IVL Case, Peripheral IVL, IVL Technology, Coronary Cases, Peripheral Cases, Shockwave C2, Shockwave M5, Shockwave S4, PulsePoint Newsletter, Coronary IVL - U.S.
PulsePoint is back! Bringing you a highlight reel of the most memorable moments, successes and key events of Q1 for both our coronary and peripheral technology. Most notably, Shockwave had a history-making moment in February of this year when we received FDA approval in the U.S. for Coronary IVL! Since then, we have seen many physicians achieving great success utilizing the technology. We also brought a new podcast, ChalkTalk, to life, and so much more we want to share with you. Check out the latest PulsePoint for the full scoop!
Topics: Coronary IVL, IVL Case, Peripheral IVL, IVL Technology, Coronary Cases, Peripheral Cases, Shockwave C2, Shockwave M5, Shockwave S4, PulsePoint Newsletter, Coronary IVL - U.S.
42 patients, 42 valves safely implanted through calcified iliofemoral access!
Topics: PAD Applications - TAVR Access, Peripheral Clinical Data, Shockwave M5
At the EPIC-SEC conference in May 2019, Dr. Chandan Devireddy performed a live case using Shockwave IVL in advance of a TAVR procedure. He tweeted about the procedure and has offered to share some additional context about the specific case, as well as the potential impact of IVL to facilitate transfemoral TAVR in the presence of calcified iliac access in general.
Topics: PAD Applications - TAVR Access, Peripheral Cases, Shockwave M5
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
